BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32222736)

  • 1. Synchronous bilateral clear cell renal cell carcinoma and prostate gland carcinoma on
    Xiao L; Zhang WJ; Ou XH; Li L
    Hell J Nucl Med; 2020; 23(1):88-89. PubMed ID: 32222736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-[
    Zhao Y; Wu C; Li W; Chen X; Li Z; Liao X; Cui Y; Zhao G; Liu M; Fu Z
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):570-579. PubMed ID: 32814979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
    Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Qi Z; Yao X; Su M; Huang R
    Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative
    Wu C; Cui Y; Zhao Y; Chen X; Liao X; Di L; Yin L; Liu M; Wang R
    Eur J Radiol; 2020 Oct; 131():109218. PubMed ID: 32882538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early assessment with
    Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
    BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
    Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
    Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three Primary Carcinomas on 18F-FDG PET/CT: Intrahepatic Cholangiocarcinoma, Papillary Renal Cell Carcinoma, and Clear Cell Renal Cell Carcinoma.
    Wu D; Hu Y; Wei Q; Tian C; Bian Y
    Clin Nucl Med; 2018 Jun; 43(6):428-430. PubMed ID: 29561526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intense Choline Activity in Renal Cell Carcinoma Without Obvious 18F-FDG Uptake.
    Xia X; Hu F; Qin C; Liu F; Lan X
    Clin Nucl Med; 2019 Jan; 44(1):38-39. PubMed ID: 30371589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
    Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
    Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesion detection by [
    Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of
    Betsunoh H; Sakamoto S; Kaji Y; Nukui A; Kobayashi M; Yashi M; Hayashi K; Anzai N; Kamai T
    Anticancer Res; 2021 Oct; 41(10):5179-5188. PubMed ID: 34593470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT of Chromophobe Renal Cell Carcinoma With Sarcomatoid Differentiation.
    Lee CH; Kesari V; Legesse T; Chen W
    Clin Nucl Med; 2018 May; 43(5):367-369. PubMed ID: 29485439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced MRI and 18F-FDG PET/CT Findings of Preoperative Primary Renal Collecting Duct Carcinoma.
    Ge J; Zuo C; Guan Y; Liang Z
    Clin Nucl Med; 2016 Dec; 41(12):998-999. PubMed ID: 27775947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.